Marshall Wace’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-310,891
| Closed | -$18.5M | – | 3209 |
|
|
2025
Q4 | $18.5M | Buy |
+310,891
| New | +$16.9M | 0.02% | 655 |
|
|
2025
Q3 | – | Sell |
-83,852
| Closed | -$4.61M | – | 2907 |
|
|
2025
Q2 | $4.61M | Buy |
83,852
+69,515
| +485% | +$4.09M | 0.01% | 1179 |
|
|
2025
Q1 | $1.01M | Sell |
14,337
-666,257
| -98% | -$44.8M | ﹤0.01% | 1774 |
|
|
2024
Q4 | $44.7M | Buy |
+680,594
| New | +$45.6M | 0.05% | 309 |
|
|
2024
Q3 | – | Sell |
-42,738
| Closed | -$3.52M | – | 2523 |
|
|
2024
Q2 | $3.52M | Sell |
42,738
-36,331
| -46% | -$3.02M | ﹤0.01% | 1138 |
|
|
2024
Q1 | $6.91M | Sell |
79,069
-352,274
| -82% | -$31.5M | 0.01% | 871 |
|
|
2023
Q4 | $41.6M | Buy |
431,343
+223,656
| +108% | +$19.8M | 0.07% | 279 |
|
|
2023
Q3 | $18.4M | Sell |
207,687
-7,635
| -4% | -$679K | 0.04% | 464 |
|
|
2023
Q2 | $18.7M | Buy |
215,322
+200,309
| +1,334% | +$18.9M | 0.04% | 505 |
|
|
2023
Q1 | $1.46M | Sell |
15,013
-585,259
| -97% | -$60.7M | ﹤0.01% | 1632 |
|
|
2022
Q4 | $62.1M | Buy |
600,272
+139,313
| +30% | +$13.1M | 0.14% | 160 |
|
|
2022
Q3 | $39.1M | Sell |
460,959
-127,659
| -22% | -$11.4M | 0.09% | 262 |
|
|
2022
Q2 | $48.8M | Buy |
588,618
+222,438
| +61% | +$17.7M | 0.1% | 209 |
|
|
2022
Q1 | $28.2M | Sell |
366,180
-263,254
| -42% | -$22M | 0.05% | 380 |
|
|
2021
Q4 | $55.6M | Buy |
629,434
+293,449
| +87% | +$24.2M | 0.1% | 194 |
|
|
2021
Q3 | $26M | Buy |
335,985
+295,034
| +720% | +$23.3M | 0.11% | 203 |
|
|
2021
Q2 | $3.42M | Buy |
+40,951
| New | +$3.25M | 0.02% | 1067 |
|
|
2021
Q1 | – | Sell |
-64,396
| Closed | -$5.65M | – | 2485 |
|
|
2020
Q4 | $5.65M | Sell |
64,396
-231,129
| -78% | -$18.3M | 0.03% | 522 |
|
|
2020
Q3 | $22.5M | Buy |
295,525
+215,264
| +268% | +$21.8M | 0.14% | 152 |
|
|
2020
Q2 | $9.9M | Buy |
80,261
+69,015
| +614% | +$6.86M | 0.07% | 289 |
|
|
2020
Q1 | $951K | Sell |
11,246
-269,525
| -96% | -$23.2M | 0.01% | 813 |
|
|
2019
Q4 | $23.7M | Buy |
280,771
+254,681
| +976% | +$19.2M | 0.16% | 147 |
|
|
2019
Q3 | $1.76M | Sell |
26,090
-256,022
| -91% | -$19.7M | 0.01% | 805 |
|
|
2019
Q2 | $24.2M | Buy |
282,112
+281,636
| +59,167% | +$24.1M | 0.2% | 104 |
|
|
2019
Q1 | $42K | Sell |
476
-31,097
| -98% | -$2.88M | ﹤0.01% | 1553 |
|
|
2018
Q4 | $2.69M | Buy |
31,573
+21,784
| +223% | +$2.07M | 0.03% | 652 |
|
|
2018
Q3 | $949K | Buy |
9,789
+6,309
| +181% | +$630K | 0.01% | 822 |
|
|
2018
Q2 | $328K | Sell |
3,480
-4,729
| -58% | -$414K | ﹤0.01% | 623 |
|
|
2018
Q1 | $666K | Buy |
8,209
+2,812
| +52% | +$241K | 0.03% | 304 |
|
|
2017
Q4 | $481K | Buy |
+5,397
| New | +$469K | 0.02% | 305 |
|
|
2017
Q3 | – | Sell |
-13,606
| Closed | -$1.24M | – | 343 |
|
|
2017
Q2 | $1.24M | Sell |
13,606
-3,897
| -22% | -$355K | 0.05% | 177 |
|
|
2017
Q1 | $1.54M | Sell |
17,503
-416,138
| -96% | -$37M | 0.07% | 175 |
|
|
2016
Q4 | $35.9M | Buy |
433,641
+294,916
| +213% | +$25.4M | 0.24% | 116 |
|
|
2016
Q3 | $12.8M | Buy |
138,725
+60,770
| +78% | +$5.72M | 0.09% | 235 |
|
|
2016
Q2 | $6.07M | Buy |
77,955
+70,744
| +981% | +$6.01M | 0.05% | 350 |
|
|
2016
Q1 | $595K | Sell |
7,211
-144,237
| -95% | -$11.7M | 0.01% | 820 |
|
|
2015
Q4 | $15.9M | Sell |
151,448
-74,724
| -33% | -$7.8M | 0.15% | 165 |
|
|
2015
Q3 | $23.8M | Buy |
226,172
+62,203
| +38% | +$8.31M | 0.29% | 89 |
|
|
2015
Q2 | $22.4M | Buy |
163,969
+12,330
| +8% | +$1.53M | 0.29% | 100 |
|
|
2015
Q1 | $18.9M | Buy |
151,639
+35,359
| +30% | +$3.75M | 0.25% | 114 |
|
|
2014
Q4 | $10.5M | Sell |
116,280
-136,881
| -54% | -$11.4M | 0.14% | 187 |
|
|
2014
Q3 | $18.3M | Sell |
253,161
-190,862
| -43% | -$12.5M | 0.26% | 109 |
|
|
2014
Q2 | $27.6M | Buy |
444,023
+439,123
| +8,962% | +$26.5M | 0.41% | 63 |
|
|
2014
Q1 | $334K | Buy |
+4,900
| New | +$361K | 0.01% | 685 |
|
Other funds holding BMRN
VCM
VPM
Marshall Wace's BMRN Position: Q1 2026 in Review
Marshall Wace sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 310,891 shares — an estimated $18.5M sold.
Marshall Wace first reported a position in BMRN in Q1 2014 and held it in 44 quarters. The position peaked at $62.1M in Q4 2022. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Marshall Wace reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Marshall Wace sold 310,891 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $18.5M.
- Marshall Wace first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 44 quarters.
- Marshall Wace's BioMarin Pharmaceuticals position peaked at $62.1M in Q4 2022.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.